Quinidine structure
|
Common Name | Quinidine | ||
|---|---|---|---|---|
| CAS Number | 56-54-2 | Molecular Weight | 324.417 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 495.9±40.0 °C at 760 mmHg | |
| Molecular Formula | C20H24N2O2 | Melting Point | 168-172 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 253.7±27.3 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of QuinidineQuinidine is an antiarrhythmic agent for the treatment of abnormal heart rhythms and also malaria. |
This table lists Chinese names, IUPAC names and various aliases of this chemical substance.
| Name | quinidine |
|---|---|
| Synonym | More Synonyms |
This table contains bioactivity, target information and biological‑assay experimental data of this compound.
| Description | Quinidine is an antiarrhythmic agent for the treatment of abnormal heart rhythms and also malaria. |
|---|---|
| Related Catalog | |
| Target |
Parasite[1] |
| In Vitro | Quinidine is a clinical anti-arrythmic drug which affects ionic currents in heart muscle and which has also been shown to be a potent blocker of several classes of K+ channel in a variety of cell types. Bath application of quinidine causes a dose-dependent reduction of the peak amplitude of Ik. The Kd for blockade of Ik at 0 mV is estimated to be 41 μM. Quinidine elicits a dose-dependent increase of the rate of the decay of Ik and this effect is enhanced by membrane depolarization. Quinidine also causes a 5 mV hyperpolarizing shift of the steady-state inactivation curve and increases the half-time for recovery from inactivation. Quinidine does not affect the onset of inactivation measured at -30 mV[1]. |
| In Vivo | Quinidine sulfate is rapidly absorbed, with peak plasma concentrations 60-90 min after an oral dose. Other salts (gluconate, polygalacturonate) are more slowly absorbed, with lower peak concentrations. Quinidine is approximately 70-90 % bound to plasma proteins. It undergoes hepatic oxidative metabolism to form an N-oxide, a 3-hydroxy form, an O-demethyl form and 2'-quinidinone. Over one-half of patients starting quinidine stop within the first year of therapy because of side effects. These include, commonly, diarrhea, nausea, and vomiting which are not necessarily related to high plasma concentrations[2]. Quinidine inhibits metabolism of amphetamine in rats. Quinidine pretreatment results in a significant decrease in the excretion of p-hydroxyamphetamine at 24 and 48 h to 7.2 and 24.1% of the vehicle-control levels, respectively, accompanied by a significant increase in amphetamine excretion between 24 and 48 h to 542% of the control[3]. |
| Animal Admin | Rats: Three rats are placed in individual metabolic cages with free access to food and water. After 24 h, urine is collected (0 h) and the rats receive the following treatment: (1) no treatment; (2) 80 mg quinidine/kg (po) at 1.0 mL/kg, and (III) 50% ethanol (1.0 mL/kg). Two hours later, all three rats receive a single dose of 15 mg amphetamine/kg (po) at 1.0 mL/kg. Urine is then collected at 24 and 48 h after the administration of quinidine. This procedure is repeated three times. After collection of urine, volume and pH are measured and the urine is stored until analysis[3]. |
| References |
This table shows physicochemical parameters including melting point, boiling point, density, solubility and optical rotation. Missing data is marked as N/A.
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 495.9±40.0 °C at 760 mmHg |
| Melting Point | 168-172 °C(lit.) |
| Molecular Formula | C20H24N2O2 |
| Molecular Weight | 324.417 |
| Flash Point | 253.7±27.3 °C |
| Exact Mass | 324.183777 |
| PSA | 45.59000 |
| LogP | 3.44 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.638 |
| InChIKey | LOUPRKONTZGTKE-LHHVKLHASA-N |
| SMILES | C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12 |
| Water Solubility | 0.05 g/100 mL (20 ºC) |
This table provides MSDS information including hazard classification, first‑aid, fire‑fighting, spill handling, operation and storage instructions.
This table summarizes toxicological test data, acute & chronic toxicity and ecological hazard parameters for this chemical.
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
This table covers safety warnings, protective measures, incompatible substances and disposal guidelines for this compound.
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn:Harmful; |
| Risk Phrases | R22 |
| Safety Phrases | S36-S22 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | VA4725000 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
| HS Code | 2933990090 |
This table presents publicly reported synthetic routes, reaction conditions, reactants and product information of the compound.
This table lists upstream starting materials and downstream derivative products related to this chemical.
| Precursor 10 | |
|---|---|
| DownStream 10 | |
This table shows customs‑related data including HS‑code, tariff and regulatory conditions for import and export.
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
This table lists relevant public references with title, journal and publication metadata for this compound.
|
Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin.
Naunyn Schmiedebergs Arch. Pharmacol. 387(9) , 883-91, (2014) Flavonoids such as quercetin and kaempferol mediate several health protective effects, e.g., anticancer effects. They are inhibitors of organic anion transporting polypeptides (OATP) and organic catio... |
|
|
Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device.
Xenobiotica 45(1) , 29-44, (2014) 1. The quantitative prediction of the pharmacokinetic parameters of a drug from data obtained using human in vitro systems remains a significant challenge i.e. prediction of metabolic clearance in hum... |
|
|
Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
Drug Metab. Pharmacokinet. 29(5) , 419-26, (2014) In central nervous system drug discovery, cerebrospinal fluid (CSF) drug concentration (C(CSF)) has been widely used as a surrogate for unbound brain concentrations (C(u,brain)). However, previous rod... |
This table contains target information, in‑vitro & in‑vivo assay data for this compound.
This table collects all English aliases, systematic names and CAS‑related synonyms of the compound.
| Conchinin |
| Chinidin |
| (S)-(6-Methoxy-4-quinolinyl)[(2R,4S,5R)-5-vinyl-1-azabicyclo[2.2.2]oct-2-yl]methanol |
| Cin-quin |
| (8R,9S)-6'-Methoxycinchonan-9-ol |
| Coccinine |
| (9S)-6'-Methoxycinchonan-9-ol |
| Quinidex |
| (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]oct-2-yl](6-methoxyquinolin-4-yl)methanol |
| Quinidine,(S)-(6-Methoxyquinolin-4-yl)((2R,4S,8R)-8-vinylquinuclidin-2-yl)methanolhydrochloride |
| Quinidine [BAN] |
| Raclopride |
| QUINDINE |
| (9S)-6-Methoxy-a-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol |
| TCMDC-131239 |
| (S)-(6-Methoxy-4-chinolinyl)[(2R,4S,5R)-5-vinyl-1-azabicyclo[2.2.2]oct-2-yl]methanol |
| Kinidin |
| MFCD00135581 |
| (S)-[(2R,4S,5R)-5-éthènyl-1-azabicyclo[2.2.2]oct-2-yl](6-méthoxy-4-quinoléinyl)méthanol |
| QUNIDINE |
| PITAYINE |
| Quinidine |
| (3a,9S)-6'-methoxycinchonan-9-ol |
| Pitayin |
| EINECS 200-279-0 |
| (9S)-6-Methoxy-α-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol |
This section contains frequently‑asked‑questions about this compound, including basic parameters, properties, storage conditions and corresponding answers.
| Q: What is the polar surface area (PSA) of quinidine? |
| A: Polar surface area (PSA) of quinidine is 45.59000. |
| Q: What is the SMILES notation of quinidine? |
| A: SMILES notation of quinidine is C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12. |
| Q: What is the InChIKey of quinidine? |
| A: InChIKey of quinidine is LOUPRKONTZGTKE-LHHVKLHASA-N. |
| Q: What are the upstream materials of quinidine? |
| A: Related upstream materials(CAS) of quinidine: 56652-53-0;657408-10-1;4363-94-4;865853-19-6;865853-23-2;865853-22-1;865853-21-0;865853-20-9;92288-15-8;35189-37-8. |
| Q: What are the downstream products of quinidine? |
| A: Related downstream products(CAS) of quinidine: 60723-43-5;524-63-0;86-68-0;84-31-1;14528-53-1;84-55-9;56-54-2;77481-82-4;599-04-2;135754-90-4. |
| Q: What is the molecular formula of quinidine? |
| A: Molecular formula of quinidine is C20H24N2O2. |
| Q: What is the melting point of quinidine? |
| A: Melting point of quinidine is 168-172 °C(lit.). |
| Q: What is the boiling point of quinidine? |
| A: Boiling point of quinidine is 495.9±40.0 °C at 760 mmHg. |
| Q: What is the molecular weight of quinidine? |
| A: Molecular weight of quinidine is 324.417. |
| Q: What is the English name of quinidine? |
| A: The English name of quinidine is quinidine. |
This table lists manufacturers and suppliers of this compound, including vendor names and product supply reference information.
| Shanghai Nianxing Industrial Co., Ltd |
| BioBioPha |
| Henan Tianfu Chemical Co., Ltd. |